Clinical Trials Browser

Completed × spartalizumab × Sarcoma × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT02658981 2023-10-06

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Phase 1 Completed

63 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT03609424 2023-01-03

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

Phase 1/2 Completed

39 enrolled

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

Phase 2 Completed

76 enrolled 14 charts

GastrointestinalLymphoidSarcomaThoracic

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

Clinical Trials

IT-01

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

PDR001 Plus Imatinib for Metastatic or Unresectable GIST

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies